Management of CKD Stage 3b with Bilateral Lower Limb Edema and Declining eGFR

Immediate Nephrology Referral

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend referring patients to nephrology immediately when eGFR is <45 mL/min/1.73 m², as this patient has crossed the critical threshold, indicating a firm need for specialist involvement 1, 2
A decline in eGFR from 49 to 39 mL/min/1.73 m² represents a >20% drop, meeting criteria for CKD progression that mandates specialist review for reversible causes and optimization of management, according to the American Journal of Kidney Diseases 3, 4
Late referral (waiting until eGFR <30) is associated with increased mortality after dialysis initiation, making timely referral at this stage critical, as stated by the Praxis Medical Insights 1

The American Journal of Kidney Diseases suggests repeating serum creatinine and eGFR within 2-4 weeks to confirm the decline is sustained rather than a transient fluctuation 3, 4
Measuring urinary albumin-to-creatinine ratio (UACR) immediately on a random spot urine sample is essential for risk stratification and determines treatment intensity, as recommended by the Praxis Medical Insights 1, 5
Ordering a complete metabolic panel, including sodium, potassium, chloride, bicarbonate, to screen for metabolic acidosis and hyperkalemia, is advised by the Praxis Medical Insights 1

Initiating or escalating loop diuretic therapy (furosemide 40-80 mg daily, titrated to effect) to achieve euvolemia and reduce preload is recommended by the Praxis Medical Insights 1
Targeting sodium restriction <2 g/day to enhance diuretic efficacy and reduce volume retention is suggested by the Praxis Medical Insights 1

The KDIGO guidelines recommend starting ACE inhibitor (lisinopril 10 mg daily) or ARB (losartan 50 mg daily) regardless of blood pressure if UACR ≥30 mg/g, as RAAS blockade reduces proteinuria and slows CKD progression (KDIGO Grade 1B recommendation) 1
Accepting up to 30% increase in serum creatinine after initiation is expected and acceptable unless volume depletion is present, as stated by the Praxis Medical Insights 1, 5

Targeting blood pressure ≤130/80 mmHg for patients with CKD and albuminuria is recommended by the Praxis Medical Insights 1
Using ACE inhibitor/ARB as first-line agent, adding calcium channel blocker or thiazide-like diuretic as second-line agents, is advised by the Praxis Medical Insights 1

The American Journal of Kidney Diseases defines CKD progression as a decline in eGFR category (G3a to G3b) and a >25% decline from baseline, confirming true progression rather than normal fluctuation 3, 4
Monitoring frequency based on risk stratification: if UACR <30 mg/g, monitor eGFR, UACR, electrolytes, blood pressure, and weight every 6 months, as recommended by the Praxis Medical Insights 1

Initiating statin therapy (atorvastatin 20-40 mg daily) for cardiovascular risk reduction, targeting LDL <100 mg/dL, is recommended by the Praxis Medical Insights 1, 2
Prescribing antiplatelet therapy (aspirin 81 mg daily) if no contraindications, as suggested by the European Heart Journal 6

Not discontinuing ACE inhibitor/ARB for creatinine increases <30% in the absence of volume depletion, as this is expected and acceptable, is advised by the Praxis Medical Insights 1, 5
Not delaying nephrology referral until eGFR <30, as this patient already meets criteria at eGFR 39 with evidence of progression, is recommended by the Praxis Medical Insights 1, 2